Sun Pharma Advanced Research Company (SPARC)
-
SPARC licences development, commercialisation rights of PDP-716, SDN-037 to Visiox Pharma
The company will receive equity in Visiox along with other financial considerations Sun Pharma Advanced Research Company (SPARC) has entered…
Read More » -
SPARC to raise Rs 1,200 cr
Issue warrants to promoter Dilip Shanghvi, others Sun Pharma Advanced Research Company (SPARC) plans to raise to Rs 1,200 crore…
Read More » -
SPARC posts positive clinical trial result for SDN-037
Sun Pharma Advanced Research Company (SPARC) has reported positive top-line results from its Phase III trial for its investigational drug,…
Read More »
